-->

Tag: Imfinzi for urothelial carcinoma

Home / Imfinzi for urothelial carcinoma

Categories

Durvalumab is approved by the USFDA for muscle invasive bladder cancer

On March 28, 2025, the Food and Drug Administration approved durvalumab (Imfinzi, AstraZeneca) to be used with gemcitabine and cisplatin as a first treatment, followed by durvalumab alone as a follow-...
imfinzi-for-urothelial-carcinoma